Melanie Senior

Healthcare Writer & Analyst at Nature portfolio; Evaluate

Speaker

I write about the science, business and politics of drug R&D for the Nature portfolio, Evaluate Pharma and Citeline. I also enjoy participating in and moderating life sciences-focused panel discussions and events across Europe and beyond.

After a First Class Natural Sciences degree from Cambridge University and two years’ post-grad research into theory of mind and language development, I began a business journalism career at the Financial Times in London. I edited the FT’s Biotechnology journal as Europe’s biotech industry came into the public consciousness; after that, I became Bureau Chief, Europe, for Elsevier Business Intelligence (subsequently Informa). Working with Real Endpoints in the US introduced me to the complex world of US reimbursement and pricing, and I was part of EY Life Sciences’ thought leadership team between 2014 and 2017.

The pace of change across science and technology is a challenge for any of us. I gained post-grad qualifications in International Health Technology Assessment (University of Sheffield), Sports Physiology & Nutrition (St Mary’s University) and Immunology (Harvard Medical School HMX). But I’m still learning, and love that my job both requires and allows me to do that.

I’m a keen runner, cyclist and swimmer and am based in London, UK, though I grew up in Luxembourg, lived in France, and have a German mum.